Banca de QUALIFICAÇÃO: VIRGINIA PAULA FRADE
Uma banca de QUALIFICAÇÃO de DOUTORADO foi cadastrada pelo programa.STUDENT : VIRGINIA PAULA FRADE
DATE: 24/11/2020
TIME: 08:30
LOCAL: Videoconferência
TITLE:
PHARMACOKINETICS OF BENZNIDAZOL AND CORRELATION PK-PDKEY WORDS:
Chagas disease, benznidazole, chronic phase
PAGES: 70
BIG AREA: Ciências da Saúde
AREA: Farmácia
SUMMARY:
Objective: The present study aimed to assess which is the best dose of benznidazole in the chronic phase of Chagas Disease, with better efficacy and less toxic effects, through a systematic review and a population pharmacokinetic model. Justification: Divergent results in research with the standard dose of 5mg / kg / day for 60 days in the chronic phase of the disease have been observed. Materials and Methods: The systematic review was conducted followed by meta-analysis and searches were performed in four databases, including studies published until May 2019. The descriptors used were: “Chagas disease”, “benznidazole”, “therapy medication ”,“ pharmacokinetics ”,“ dose-response relationship, medication ”and“ chronic disease ”. The meta-analysis compared studies using the standard dose of 5 mg / kg / day for 30 or 60 days. For the construction of the population kinetics model, a prospective cohort was carried out, in which patients with chronic Chagas' disease who are followed up at the Instituto de Infectologia Emílio Ribas were approached. Benznidazole was prescribed at a dose of 5mg / kg / day for 8/8 hours for 60 days. Two weeks after the start of treatment, blood samples were obtained to determine the concentration of the drug. Adverse events were assessed using a standardized questionnaire. Partial Results: In the systematic review, 23 articles were included and, of these, nine were selected for the meta-analysis. The selected studies were published between 1996 and 2018, with benznidazole dose regimens ranging from 2.5 mg / kg / day to 10mg / kg / day, lasting 30 to 80 days of treatment. Researches that used the standard dose for 30 days showed better results for the observed parameters (CRP, cardiac changes and negative serology) compared to those that used for 60 days. The prospective cohort included ten patients, with an average age of 50.3 years (SD = 5.62), the majority of whom were brown (90.0%) and female (60.0%). Adverse events have been reported after starting treatment, namely: diarrhea, pruritus, hypogeusia, liver dysfunction, oro-labial herpes, paresthesia, peripheral neuropathy, epigastric pain, dyspepsia / constipation and arthromyalgia. Conclusions: The results of the systematic review pointed to a great diversity of dosing schedules, indicating that there is still no consensus on the ideal dose schedule for benznidazole in the chronic phase of Chagas disease.
BANKING MEMBERS:
Externo à Instituição - JOSÉ EDUARDO GONÇALVES - UFMG
Externa à Instituição - KARIN VERA LÓPEZ
Presidente - 1084423 - RAFAEL GONCALVES TEIXEIRA NETO